Medivir’s ADRs have no independent price-discovery function, so you might as well concern yourself only with the price action in Stockholm.
Can you expand on your response here? The ADRs should, in theory, trade in step with the Stockholm shares, right? If so, is it just delayed reaction to market carnage for the ADRs that accounts for the large divergence today?